Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy

Oh, Eonju; Oh, Jung Eun; Hong, Jin; Chung, Yoon Ho; Lee, Yunki; Парк, Ки Донг; Kim, Sung Wan; Yun, Chae Ok

doi:10.1016/j.jconrel.2017.03.028

Cited by 73 publications

(74 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It requires synergistic or additive combination approach with other anti-cancer therapies for an improved therapeutic outcome [19,25,76,148,150,151]. Similar to OHSV-IL12, a combination immunotherapeutic approach is also required to enhance anti-tumor efficacy of other OVs encoding IL-12 [49,134,136,138,139].…”

Section: Discussionmentioning

confidence: 99%

“…Ad-TD-IL-12, but not Ad-TD-nsIL-12 resulted in a significant increase in CD3 + CD4 − CD8 + populations in the spleen Level of splenic IFN-γ, IP-10 and lymph node IFN-γ were lower in Ad-TD-nsIL-12 compared to Ad-TD-IL-12 treated hamster. [136] in serum and tumor. [42,43] Ad-TD-IL-12, Ad-TD-nsIL-12…”

Section: Il-12 Insertion Does Not Compromise Safety and Tumor Specifimentioning

confidence: 99%

“…Several other OVs encoding IL-12 have been developed ( Table 2), including adenoviruses [18,42,[46][47][48][49][133][134][135][136][137][138], measles virus [20,50], maraba virus [51], Newcastle disease virus [52], Semliki forest virus [53][54][55][56][139][140][141], vesicular stomatitis virus [57,142], and Sindbis virus [58]. In these above-mentioned studies, IL-12 is expressed either alone [18,20,51,57,[137][138][139] or co-expressed alongside with GM-CSF [134][135][136], pericellular matrix proteoglycan decorin [47], tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [133], IL-2 proinflammatory cytokine [52], IFN-γ inducing factor IL-18 [46], T cell co-stimulatory ligand 4-1BBL [49], CD8 + co-receptor for CD28 and CTLA-4 [48], or suicide genes [42]. The anti-tumor efficacy of these engineered OVs are...…”

Section: Anti-cancer Potential Of Other Ovs Encoding Il-12mentioning

confidence: 99%

“…In these above-mentioned studies, IL-12 is expressed either alone [18,20,51,57,[137][138][139] or co-expressed alongside with GM-CSF [134][135][136], pericellular matrix proteoglycan decorin [47], tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [133], IL-2 proinflammatory cytokine [52], IFN-γ inducing factor IL-18 [46], T cell co-stimulatory ligand 4-1BBL [49], CD8 + co-receptor for CD28 and CTLA-4 [48], or suicide genes [42]. The anti-tumor efficacy of these engineered OVs are tested in various mouse or hamster pre-clinical cancer models and produce superior anti-tumor immunity either alone [18,20,42,[46][47][48]51,52,57,133,135,137] or in combination with other immunotherapeutic agents such as dendritic cell (DC) vaccine [49,134,136], ICI anti-PD-1 and anti-PD-L1 [139], or cytokine-induced killer cells [138].…”

Section: Anti-cancer Potential Of Other Ovs Encoding Il-12mentioning

confidence: 99%

See 3 more Smart Citations

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

Nguyen

Guz-Montgomery

Saha

2020

Cells

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are genetically modified or naturally occurring viruses, which preferentially replicate in and kill cancer cells while sparing healthy cells, and induce anti-tumor immunity. OV-induced tumor immunity can be enhanced through viral expression of anti-tumor cytokines such as interleukin 12 (IL-12). IL-12 is a potent anti-cancer agent that promotes T-helper 1 (Th1) differentiation, facilitates T-cell-mediated killing of cancer cells, and inhibits tumor angiogenesis. Despite success in preclinical models, systemic IL-12 therapy is associated with significant toxicity in humans. Therefore, to utilize the therapeutic potential of IL-12 in OV-based cancer therapy, 25 different IL-12 expressing OVs (OV-IL12s) have been genetically engineered for local IL-12 production and tested preclinically in various cancer models. Among OV-IL12s, oncolytic herpes simplex virus encoding IL-12 (OHSV-IL12) is the furthest along in the clinic. IL-12 expression locally in the tumors avoids systemic toxicity while inducing an efficient anti-tumor immunity and synergizes with anti-angiogenic drugs or immunomodulators without compromising safety. Despite the rapidly rising interest, there are no current reviews on OV-IL12s that exploit their potential efficacy and safety to translate into human subjects. In this article, we will discuss safety, tumor-specificity, and anti-tumor immune/anti-angiogenic effects of OHSV-IL12 as mono-and combination-therapies. In addition to OHSV-IL12 viruses, we will also review other IL-12-expressing OVs and their application in cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Il-12 Insertion Does Not Compromise Safety and Tumor Specifimentioning

confidence: 99%

Section: Anti-cancer Potential Of Other Ovs Encoding Il-12mentioning

confidence: 99%

Section: Anti-cancer Potential Of Other Ovs Encoding Il-12mentioning

confidence: 99%

See 2 more Smart Citations

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

Nguyen

Guz-Montgomery

Saha

2020

Cells

View full text Add to dashboard Cite

show abstract

“…They extend the presence of therapy at the tumour site by gradually releasing treatment as they degrade, improving treatment efficacy and avoiding excessive treatment loss to neighbouring tissue or the lymphatic system. Sustained-delivery systems have improved the effectiveness of a range of cancer treatments, including chemotherapy [2,3], oncolytic virotherapy [4][5][6][7] and immunotherapy [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Optimising Hydrogel Release Profiles for Viro-Immunotherapy Using Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Immature Dendritic Cells

et al. 2020

Self Cite

View full text Add to dashboard Cite

Sustained-release delivery systems, such as hydrogels, significantly improve cancer therapies by extending the treatment efficacy and avoiding excess wash-out. Combined virotherapy and immunotherapy (viro-immunotherapy) is naturally improved by these sustained-release systems, as it relies on the continual stimulation of the antitumour immune response. In this article, we consider a previously developed viro-immunotherapy treatment where oncolytic viruses that are genetically engineered to infect and lyse cancer cells are loaded onto hydrogels with immature dendritic cells (DCs). The time-dependent release of virus and immune cells results in a prolonged cancer cell killing from both the virus and activated immune cells. Although effective, a major challenge is optimising the release profile of the virus and immature DCs from the gel so as to obtain a minimum tumour size. Using a system of ordinary differential equations calibrated to experimental results, we undertake a novel numerical investigation of different gel-release profiles to determine the optimal release profile for this viro-immunotherapy. Using a data-calibrated mathematical model, we show that if the virus is released rapidly within the first few days and the DCs are released for two weeks, the tumour burden can be significantly decreased. We then find the true optimal gel-release kinetics using a genetic algorithm and suggest that complex profiles present unnecessary risk and that a simple linear-release model is optimal. In this work, insight is provided into a fundamental problem in the growing field of sustained-delivery systems using mathematical modelling and analysis.

show abstract

Engineered Bio‐Based Hydrogels for Cancer Immunotherapy

Peng,

Liang,

Meng

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Immunotherapy represents a revolutionary paradigm in cancer management, showcasing its potential to impede tumor metastasis and recurrence. Nonetheless, challenges including limited therapeutic efficacy and severe immune‐related side effects are frequently encountered, especially in solid tumors. Hydrogels, a class of versatile materials featuring well‐hydrated structures widely used in biomedicine, offer a promising platform for encapsulating and releasing small molecule drugs, biomacromolecules, and cells in a controlled manner. Immunomodulatory hydrogels present unique capability for augmenting immune activation and mitigating systemic toxicity through encapsulation of multiple components and localized administration. Notably, hydrogels based on biopolymers have gained significant interest owing to their biocompatibility, environmental friendliness, and ease of production. This review delves into the recent advances in bio‐based hydrogels in cancer immunotherapy and synergistic combinatorial approaches, highlighting their diverse applications. We anticipate that this review will guide the rational design of hydrogels in the field of cancer immunotherapy, fostering clinical translation and ultimately benefiting patients.This article is protected by copyright. All rights reserved

show abstract

Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy

Cited by 73 publications

References 40 publications

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

Optimising Hydrogel Release Profiles for Viro-Immunotherapy Using Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Immature Dendritic Cells

Engineered Bio‐Based Hydrogels for Cancer Immunotherapy

Contact Info

Product

Resources

About